Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,shortLongTermDebt,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,issuanceOfStock,otherCashflowsFromInvestingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,currency,epsCurrentYear,market,shortName,exchange,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,exchangeDataDelayedBy,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,EIGR,109125000.0,33951300,14302000,,-19163000,,-19174000,5886000,1827000,-18361000,-18361000,,-880000,,,,11000,2097000,20458000,270000,-802000,,-19174000,-19174000,405523000.0,47713000.0,109125000.0,899000.0,156838000.0,34000.0,1310000.0,-296426000.0,-6000.0,4085000.0,65056000.0,15875000.0,-6000.0,1524000.0,118803000.0,32426000.0,42311000.0,1438000.0,31403000.0,2065000.0,4444000.0,,-22822000.0,-3270000.0,-22898000.0,-72000.0,852000.0,-43354000.0,-10000.0,-20384000.0,214000.0,-668000.0,-799000.0,-62000.0,2461000.0,-76000.0,,,102928000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,8.115,1630507788,-0.025000572,8.11,8.22,8.0406,28945,-10.272151,2.805,8.124444,-0.009444237,-0.0011624472,8.672681,-0.5576811,-0.0643032,275514784,-4.5335197,2.893048,15,America/New_York,EDT,False,False,USD,-0.79,us_market,"Eiger BioPharmaceuticals, Inc.",NGM,REGULAR,2,-0.30713233,8.0406 - 8.22,8.14,8.04,8.09,10,9,finmb_52776077,NasdaqGM,"Eiger BioPharmaceuticals, Inc.",USD,183084,154850,0.78499985,0.10709412,7.33 - 13.49,-5.375,-0.3984433,7.33,13.49,1620331200,1635937140,0,1636372800,-2.311,-1.79,-14400000,1.33,,,13.49,7.33,8.12,8.67,183.08k,154.85k,33.95M,,30.58M,1.22%,69.66%,886.57k,6.7,3.02%,2.61%,865.5k,,,,,,0.00%,,,1:15,"Mar 22, 2016","Dec 30, 2020","Jun 29, 2021",0.00%,"-1,166.19%",-32.20%,-29.13%,5.74M,0.18,,,-66.74M,-24.41M,-2.31,,107.37M,3.16,32.43M,29.72,7.48,2.81,-64.94M,-38.52M,Value,94306,Healthcare,35,9,8,"Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.",Palo Alto,650 272 6138,CA,8,1609372800,1625097600,5,United States,http://www.eigerbio.com,86400,7,2155 Park Boulevard,650 618 1621,Biotechnology
t-1,EIGR,126190000.0,33951300,13842000,,29267000,,29248000,5564000,3593000,-15813000,-15813000,,-885000,,,,19000,3646000,19459000,53000,45080000,,29248000,29248000,403413000.0,49325000.0,126190000.0,537000.0,175515000.0,34000.0,1941000.0,-277252000.0,-5000.0,3921000.0,108410000.0,17517000.0,-5000.0,1708000.0,169886000.0,,52082000.0,639000.0,31218000.0,1397000.0,7747000.0,,47706000.0,3175000.0,94464000.0,15000.0,-825000.0,79546000.0,-10000.0,-14933000.0,194000.0,-1304000.0,-639000.0,-297000.0,-44782000.0,-16000.0,312000.0,46493000.0,152369000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,8.115,1630507788,-0.025000572,8.11,8.22,8.0406,28945,-10.272151,2.805,8.124444,-0.009444237,-0.0011624472,8.672681,-0.5576811,-0.0643032,275514784,-4.5335197,2.893048,15,America/New_York,EDT,False,False,USD,-0.79,us_market,"Eiger BioPharmaceuticals, Inc.",NGM,REGULAR,2,-0.30713233,8.0406 - 8.22,8.14,8.04,8.09,10,9,finmb_52776077,NasdaqGM,"Eiger BioPharmaceuticals, Inc.",USD,183084,154850,0.78499985,0.10709412,7.33 - 13.49,-5.375,-0.3984433,7.33,13.49,1620331200,1635937140,0,1636372800,-2.311,-1.79,-14400000,1.33,,,13.49,7.33,8.12,8.67,183.08k,154.85k,33.95M,,30.58M,1.22%,69.66%,886.57k,6.7,3.02%,2.61%,865.5k,,,,,,0.00%,,,1:15,"Mar 22, 2016","Dec 30, 2020","Jun 29, 2021",0.00%,"-1,166.19%",-32.20%,-29.13%,5.74M,0.18,,,-66.74M,-24.41M,-2.31,,107.37M,3.16,32.43M,29.72,7.48,2.81,-64.94M,-38.52M,Value,94306,Healthcare,35,9,8,"Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.",Palo Alto,650 272 6138,CA,8,1609372800,1625097600,5,United States,http://www.eigerbio.com,86400,7,2155 Park Boulevard,650 618 1621,Biotechnology
t-2,EIGR,95035000.0,33951300,12545000,,-18806000,,-18806000,5418000,0,-17963000,-17963000,,-913000,,,,0,0,17963000,0,-843000,,-18806000,-18806000,401509000.0,48559000.0,95035000.0,,143594000.0,34000.0,1215000.0,-306500000.0,-8000.0,3903000.0,28864000.0,16627000.0,-8000.0,1885000.0,137806000.0,,99976000.0,,31194000.0,,4640000.0,,-26816000.0,-3735000.0,-26967000.0,19353000.0,4989000.0,-23129000.0,-10000.0,-15515000.0,179000.0,-1304000.0,-639000.0,-22000.0,1858000.0,-151000.0,19375000.0,46493000.0,121179000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,8.115,1630507788,-0.025000572,8.11,8.22,8.0406,28945,-10.272151,2.805,8.124444,-0.009444237,-0.0011624472,8.672681,-0.5576811,-0.0643032,275514784,-4.5335197,2.893048,15,America/New_York,EDT,False,False,USD,-0.79,us_market,"Eiger BioPharmaceuticals, Inc.",NGM,REGULAR,2,-0.30713233,8.0406 - 8.22,8.14,8.04,8.09,10,9,finmb_52776077,NasdaqGM,"Eiger BioPharmaceuticals, Inc.",USD,183084,154850,0.78499985,0.10709412,7.33 - 13.49,-5.375,-0.3984433,7.33,13.49,1620331200,1635937140,0,1636372800,-2.311,-1.79,-14400000,1.33,,,13.49,7.33,8.12,8.67,183.08k,154.85k,33.95M,,30.58M,1.22%,69.66%,886.57k,6.7,3.02%,2.61%,865.5k,,,,,,0.00%,,,1:15,"Mar 22, 2016","Dec 30, 2020","Jun 29, 2021",0.00%,"-1,166.19%",-32.20%,-29.13%,5.74M,0.18,,,-66.74M,-24.41M,-2.31,,107.37M,3.16,32.43M,29.72,7.48,2.81,-64.94M,-38.52M,Value,94306,Healthcare,35,9,8,"Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.",Palo Alto,650 272 6138,CA,8,1609372800,1625097600,5,United States,http://www.eigerbio.com,86400,7,2155 Park Boulevard,650 618 1621,Biotechnology
t-3,EIGR,92950000.0,33951300,9810000,,-15680000,,-15680000,5027000,0,-14837000,-14837000,,-906000,,,,0,0,14837000,0,-843000,,-15680000,-15680000,380596000.0,47743000.0,92950000.0,,140693000.0,32000.0,803000.0,-287694000.0,16000.0,3781000.0,51993000.0,21660000.0,16000.0,1970000.0,134942000.0,,73341000.0,,25200000.0,,8250000.0,5783000.0,-45420000.0,3070000.0,-45429000.0,48717000.0,-3377000.0,-10820000.0,-10000.0,-14108000.0,161000.0,-1304000.0,-639000.0,-22000.0,1718000.0,-9000.0,48717000.0,46493000.0,113282000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,8.115,1630507788,-0.025000572,8.11,8.22,8.0406,28945,-10.272151,2.805,8.124444,-0.009444237,-0.0011624472,8.672681,-0.5576811,-0.0643032,275514784,-4.5335197,2.893048,15,America/New_York,EDT,False,False,USD,-0.79,us_market,"Eiger BioPharmaceuticals, Inc.",NGM,REGULAR,2,-0.30713233,8.0406 - 8.22,8.14,8.04,8.09,10,9,finmb_52776077,NasdaqGM,"Eiger BioPharmaceuticals, Inc.",USD,183084,154850,0.78499985,0.10709412,7.33 - 13.49,-5.375,-0.3984433,7.33,13.49,1620331200,1635937140,0,1636372800,-2.311,-1.79,-14400000,1.33,,,13.49,7.33,8.12,8.67,183.08k,154.85k,33.95M,,30.58M,1.22%,69.66%,886.57k,6.7,3.02%,2.61%,865.5k,,,,,,0.00%,,,1:15,"Mar 22, 2016","Dec 30, 2020","Jun 29, 2021",0.00%,"-1,166.19%",-32.20%,-29.13%,5.74M,0.18,,,-66.74M,-24.41M,-2.31,,107.37M,3.16,32.43M,29.72,7.48,2.81,-64.94M,-38.52M,Value,94306,Healthcare,35,9,8,"Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.",Palo Alto,650 272 6138,CA,8,1609372800,1625097600,5,United States,http://www.eigerbio.com,86400,7,2155 Park Boulevard,650 618 1621,Biotechnology
